Skip to Main Content

Rival biotechs Alnylam and Dicerna are announcing a ceasefire.

The two companies, which are both developing drugs based on the Nobel Prize-winning technique known as RNA interference, announced an accord Monday intended to harmonize two of their drug programs. The biotechs are working on two sets of rival drug candidates: Each has a drug candidate that targets alpha-1 antitrypsin deficiency — a rare genetic disease that affects a person’s lungs and liver, and each also has a candidate that targets primary hyperoxaluria type 1, a rare genetic disorder.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!